Management Of Emergency Adverse Effects Of Cart Cell Therapy In Hematologic Cancers

Abstract

Hematological cancers, such as lymphoma and leukemia, have been successfully treated with Chimeric antigen receptor (CAR) T cells. Several CAR T-cell medicines have already received approval, and more are being tested with similar indications or expanded to treat other cancers. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are possible serious or even fatal complications of CAR T-cell therapy. Due to this, medical emergency teams (MET) are being called upon more frequently to evaluate and treat CAR T-cell consumers. To provide METs a survival manual with a suggested care protocol, this article highlights the main problems and therapeutic procedures that follow the fundamental CAR T-cell therapy principles.